EBE announces its 2018-2020 Board of Directors
Brussels, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE), is pleased to announce its Board of Directors for 2018-2020, following the decisions taken at the EBE Annual Meeting on 26 June 2018.
EBE has appointed a new president, Ahmed Bouzidi and a new vice-president, François Martelet. Dr Bouzidi has been a board member of EBE since its inception until 2003, re-joining the EBE Board in 2012. Dr Martelet has served on the EBE Board since 2011. Both will be stepping into new leadership roles within the board.
Ahmed Bouzidi is the founder and Chief Executive Officer of Vaxeal Holding SA, a leading SME pioneer in immuno-oncology. He previously founded and managed the leading biotech pioneers, SEDAC-Therapeutics Inc. and Biophysiomics Holding Inc. He also held senior advisory positions with high-level Chinese healthcare stakeholders, and worked as a senior researcher at the LFB for a decade. Dr Bouzidi holds a Master degree in Animal Biology from University of Lille (France) and a PhD in Cellular Biology and an MBA in Finance from University of New Hampshire, Durham (USA).
François Martelet currently serves as Chief Executive Officer at NetScientific PLC which he joined in 2015. NetScientific is a healthcare technology IP commercialisation group with a focus on sourcing, funding and commercialising technologies improving the health and well-being of people with chronic diseases. He has more than two decades of experience in biopharma and has a track record for shaping and developing businesses to deliver returns, having held senior leadership positions in a range of large and smaller pharmaceutical and biopharmaceutical companies. Dr Martelet holds a Doctorate in Medicine and a Master’s degree in Business from Dijon University, and a degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD. François Martelet’s awards include the Pasteur Institute medal (1989), Knight of the French National Order Merit (2011) and Knight of the Legion d’Honneur (2017), the highest decoration in France.
The EBE Board leadership is completed by Didier Malherbe, Vice President Public Affairs at UCB and Managing Director at UCB Belgium, who continues to serve as EBE’s treasurer.
In addition to a new president and vice president, EBE also appointed four new Board members: Erik Bogsch (Deputy Director and Head of R&D and Manufacturing, Biotechnology business unit of Gedeon Richter, for PregLem), Ingmar Hoerr (Co-Founder/Chairman of the Supervisory Board, Curevac AG), Maria Pascual (VP Regulatory Affairs & Corporate QA, TiGenix) and Manos Perros (President & Chief Executive Officer, Entasis Therapeutics).
Michele Antonelli (President, Stallergenes SAS, and Executive Vice President, Head of Europe & International, Stallergenes-Greer), Nicola Beaucamp (Head of Process Research in Pharma Research & Early Development, Roche Diagnostics GmbH), Roberto Gradnik (Chief Executive Officer at Ixaltis), Jochen Maas (General Manager R&D at Sanofi Aventis Germany) and Jacky Vonderscher (Chief Executive Officer at ENYO Pharma SA) have all been re-elected to serve on the board for the 2018-2020 term.
“I would like to thank Eduardo Bravo and Andrea Chiesi, the previous president and vice-president, for their great job over the past two years. I am honoured to take on this role at such an important time for EBE. I very much look forward to working with François and our colleagues to tackle the many exciting opportunities and challenges being presented by the biopharmaceutical industry in Europe”, said Ahmed Bouzidi.
“I am delighted to offer my experience from both big pharmaceutical companies and SMEs to the EBE board in order to ultimately improve patients’ lives which should be our final goal through a close relationship with our working groups”, said Francois Martelet.
“We are delighted with the strong leadership experience of the EBE Board of Directors for 2018-2020” added Barbara Freischem, Executive Director EBE, ”I am excited to work with the new board”.
To see the EBE Governance page, please click here.
European Biopharmaceutical Enterprises (EBE) represents the voice of biopharmaceutical companies of all sizes in Europe and is a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA). It currently has 56 members – the majority of which are small and medium sized companies – engaged in the research, development, manufacturing and marketing of new medicinal products using biotechnology.
To learn more about EBE, visit www.ebe-biopharma.org
Barbara Freischem, Executive Director
European Biopharmaceutical Enterprises – EBE
Tel: +32 2 626 25 64